XPH Looks Tempting, but the Five-Year Chart Warns Investors
SPDR S&P Pharmaceuticals ETF has delivered a standout one-year run, yet the longer five-year view casts a shadow. The...
This quick comparison explains why price indices and total return indices diverge, focusing on dividends and reinvestment effects.
28,657 articlesSPDR S&P Pharmaceuticals ETF has delivered a standout one-year run, yet the longer five-year view casts a shadow. The...
Imagine a future where spacex worth more than Amazon becomes market reality. This article lays out the drivers, scena...
Non-US markets rebound as the dollar weakens, prompting retirees to seek ESG-friendly exposure that also delivers div...
A veteran fund manager who compiles a 40%-a-year track record remains bullish on semiconductors, arguing the next wav...
A rising number of Americans are pursuing financial independence without a six-figure salary, emphasizing budgeting, ...
A seasoned financial planner argues that a two-ETF approach can cover most retirement needs, pairing a dividend-based...
A single viral moment can ripple through markets and your wallet. This guide explains how media buzz affects money de...
A new set of futures is coming to the CME Group, tying Tesla and SpaceX to a cash-settled futures contract. This arti...
In a dividend aristocrats shaky market, Coca-Cola, Procter & Gamble, Johnson & Johnson, McDonald's, and Colgate-Palmo...
Tech stocks lead early gains as oil eases and AI developments grab attention. The live Nasdaq Composite shows tech st...
As GTC 2026 nears, Nvidia, Broadcom, and Coherent gear up for major AI hardware unveilings. Analysts see potential fo...
Markets show the U.S. dollar rising as Iran tensions mount, while select crypto assets climb, creating an unusual cro...